


**Fig. 3.** Effect of nicotine on the expression of costimulatory/coinhibitory molecules on DCs. Expression of HLA-DR(A), CD40(A), CD80(B), CD86(B), PD-L1(C), PD-L2(C), ILT3(D) and ILT4 (D) on MoDCs or NiDCs stimulated with LPS (10 ng/ml) for 48 h was evaluated by FACS. Left panels: bar graphs are shown as mean values  $\pm$  SD of five independent experiments. \* $P < 0.05$  when compared with MoDCs stimulated with LPS. MFI: mean fluorescent intensity. Right panels: one representative FACS histogram of MoDCs (thin line) and NiDCs (thick line) of more than six independent experiments are shown.


tobacco toxicity that alters immune function. Considering the many components of cigarette smoke, nicotine may not be responsible for all types of tobacco toxicity. The expression of nicotinic acetylcholine receptors, however, indicates that the effects of nicotine may be transmitted and mediated by a specific cellular signaling pathway(s) coupled to immunological function. Although  $10^{-3}$  M nicotine is greater than the pharmacological dose, the concentration of nicotine in saliva of smokers may reach mM levels in localized areas such as the oral cavity and respiratory tract [14–16]. We therefore assumed that direct and local exposure of high doses of nicotine to the inflammatory lesion with bleeding in gingival tissue initiates monocytes to differentiate into DC in inflamed gingival

microcirculation. In preliminary experiments, we used  $10^{-8}$  to  $10^{-2}$  M nicotine to investigate the effect of nicotine on DC phenotypic changes, and found that  $10^{-3}$  M nicotine significantly induced DC characteristics. Additionally, we confirmed that  $10^{-3}$  M nicotine did not impact DC viability. Therefore, we chose  $10^{-3}$  M nicotine to induce differentiation of monocytes into DCs.


We report that *in vitro* differentiation of DCs from monocytes in the presence of nicotine yields a subset of DC (NiDCs) characterized by an altered phenotypic profile and modulated functions. CD1a is one of five members of the CD1 family and has been used as a DC biomarker [40]. There is however a significant heterogeneity in CD1a expression in DCs. Both CD1a (+ or -) DCs have been



**Fig. 4.** Expression and activation of PPAR  $\gamma$  in MoDCs and NiDCs. (A) Representative RT-PCR analysis of PPAR  $\gamma$  mRNA expression. One representative profile of six performed. (B) Quantitative analyses of PPAR  $\gamma$  mRNA expression by real-time RT-PCR. mRNA levels are expressed as fold change above control mRNA (HPRT). Results are shown as mean values  $\pm$  SD of five independent experiments. (C) Activation of PPAR  $\gamma$  in MoDCs and NiDCs. Nuclear extracts taken at a half-hour were analyzed by the TransAM PPAR  $\gamma$  assay. Results are shown as mean values  $\pm$  SD of five independent experiments and are expressed as ratio of OD<sub>450</sub>. (D) Expression of the PPAR  $\gamma$  target genes in MoDCs and NiDCs. Results are shown as mean values  $\pm$  SD of five independent experiments. \**P* < 0.05 when compared with MoDCs.



**Fig. 5.** Effect of d-tubocurarine, a non-selective nAChRs antagonist on mRNA expression of PPAR  $\gamma$  and PPAR  $\gamma$  target genes in MoDCs and NiDCs. (A) Expression of CD1a was examined at day 7 to evaluate the effect of nicotine and d-tubocurarine. Results are shown as mean values  $\pm$  SD of five independent experiments. (B–D) Quantitative analyses of PPAR  $\gamma$ , ADFP, and ApoE mRNA expression by real-time RT-PCR. mRNA levels are expressed as fold change above control mRNA (HPRT). Results are shown as mean values  $\pm$  SD of four independent experiments. \**P* < 0.05 when compared with DCs differentiated in the presence of nicotine with pretreatment of d-tubocurarine.



**Fig. 6.** Effect of d-tubocurarine, non-selective nAChRs antagonist on Th1 responses in MoDCs and NiDCs. (A) IL-12 (p40 + p70) production by MoDCs and NiDCs. MoDCs and NiDCs pretreated with d-tubocurarine (1  $\mu$ M) were cultured in the presence of 10 ng/ml LPS for 48 h. Supernatants were then tested for IL-12 (p40 + p70) production by ELISA. (B) Supernatants of restimulated T cells were harvested and measured for IFN- $\gamma$  level by ELISA. Results are shown as mean values  $\pm$  SD of four independent experiments. \**P* < 0.05 when compared with NiDCs without pretreatment of d-tubocurarine.

[42–45]. In our study, a significant reduction of CD1a<sup>+</sup> expression is observed in NiDCs when compared with MoDCs. The effect of nicotine on decreasing CD1a expression is inhibited by pretreatment of cells with d-tubocurarine, a non-selective nAChR antagonist. These results indicate that nicotine interaction with nAChRs can mediate DC differentiation.

As seen in Fig. 1B, LPS-stimulated NiDC secreted lower amounts of pro-inflammatory cytokines such as IL-12 (p40 + p70) and TNF- $\alpha$ , compared with MoDCs. These data confirm results from previous studies in which nicotine and cigarette smoke extracts (CSE) suppressed DC function, impaired antigen-presentation to induce naive T cell proliferation and alter Th1 responses into those seen in Th2 cells [23,24]. These studies also described that CSE suppressed IL-12 production in activated DCs, and diminished the effects of costimulatory molecules such as CD40 and CD80. We observed poor induction of T cell proliferation by NiDCs, elevation of the coinhibitory molecules PD-L1 and ILT4, and a slight

identified in peripheral blood [41]. In addition, recent studies suggest that the ratio of +/- forms of CD1a DCs differentiated from monocytes can be altered depending on the culture conditions

upregulation of PD-L2 in LPS-stimulated NiDCs. Furthermore, ILT3 expression was maintained in NiDC after LPS-stimulation, although expression on LPS-stimulated MoDCs was reduced. Increased PD-L1 and PD-L2 expression combined with positive costimulatory molecules such as CD86 induce an immunotolerogenic function in DCs [46–48]. In addition, high expression of ILT3 and ILT4 on DCs is associated with immunotolerogenic characteristics [49,50]. The reduction in priming capacity of NiDCs may result from induction of inhibitory cell surface receptors.

PPAR  $\gamma$  has been reported to mediate several DC functions. PPAR  $\gamma$ -activated DCs altered the differentiation of naive CD4 T cells into Th2 cells [32,51]. In addition, PPAR- $\gamma$  agonists inhibited TLR-mediated DC activation by interfering with the NF- $\kappa$ B and MAP kinase pathway [52]. In a conditional PPAR  $\gamma$  knockout mouse study, PPAR  $\gamma$ -activated DCs induced naive T cell anergy [31]. Other studies suggest that PPAR  $\gamma$  plays an important role in induction and maintenance of natural and induced Treg cells [53,54]. A recent report described that activation of PPAR  $\gamma$  strongly enhanced the expression of B7H1 (also termed PD-L1) [55]. We show that expression of PPAR- $\gamma$  gene and PPAR- $\gamma$  target genes are upregulated in NiDCs. ApoE plays important roles in lipoprotein clearance and homeostasis. ADRP plays a role in lipid body formation and cross-presentation of phagocytosed antigens to CD8<sup>+</sup> T cells. FABP4 plays an important role in the regulation of insulin sensitivity. In addition, both ApoE and FABP4 deficiency lead to development of atherosclerosis. Among those molecules, ADRP is likely to have a role in DC antigen presenting function. However, there is no information at present that these genes are involved in T cell proliferation and differentiation. With regard to PPAR- $\gamma$  expression in NiDCs, further studies are needed to investigate the possible role of nicotine in induction of Treg cells as our data suggests that nicotine may differentiate monocytes into tolerogenic DCs.

The molecular mechanism of elevated PPAR  $\gamma$  expression in NiDCs needs to be clarified. Results from recent studies indicate that  $\alpha$ 7nAChR is crucial to the regulation of systemic inflammation, and that nicotine and acetylcholine control inflammatory cytokine production from endotoxin-stimulated macrophages by inhibiting NF- $\kappa$ B pathway via  $\alpha$ 7nAChRs [11,13]. We demonstrate that pre-treatment of DCs with d-tubocurarine, a non-selective nAChR antagonist, reversed inhibition of CD1a expression, IL-12 production and Th1 responses in the presence of nicotine. One point that appears to be clear is that nicotine and nicotinic agonists prevent endotoxin-induced activation of the NF- $\kappa$ B pathway and induce expression of PPAR  $\gamma$ . Upregulation of PPAR  $\gamma$  and downregulation of NF- $\kappa$ B may synergistically induce the NiDC phenotype described previously. Blocking nAChRs by antagonist recovered Th1 response, however, there was no significant difference in IL-5 and IL-10 production between antagonist-treated NiDCs and control-NiDCs (data not shown). Presumably, the pathway inducing Th2 immune responses may be influenced by endocytosed nicotine, and not only by nicotine acting via nAChRs signaling.

Cigarette smoking leads to many health problems worldwide by significantly increasing the risk of diseases such as lung cancer, cardiovascular disease, COPD, rheumatoid arthritis and periodontal disease [1–5,56–58]. Smoking-related suppression of immune responses includes reduction of NK activity [59], and inhibition of microbicidal activity of macrophages [8,60]. Cigarette smoking and nicotine, however, may actually reduce severe inflammation in patients with ulcerative colitis (UC) [61,62]. In an animal study, conditional deletion of the PPAR  $\gamma$ -encoded gene in intestinal epithelial cells or macrophages caused an exacerbation of experimental colitis [30,53]. In addition, PPAR  $\gamma$  expression in the colonic mucosa is impaired in UC patients [63]. Results from these studies in addition to results from our study, indicate that nicotine signaling may induce expression and activation of PPAR  $\gamma$ .

In conclusion, our study provides new data indicating that nicotine reduces inflammatory cytokine production, and suppresses T cell priming capacity of DC via nAChRs. The suggested mechanism is nicotinic upregulation of coinhibitory molecules. The effect of nicotine may be mediated by PPAR  $\gamma$  expression. These studies suggest a link between the effects of nicotine on DC function and smoking-related diseases. Understanding the immuno-modulatory effects of nicotine will provide new and useful information for the prevention of smoking-related diseases.

## Acknowledgments

This work was supported in part by Grants-in-Aid from the Japan Society for the Promotion of Science (17791554, 20592427, 21890136). This work was also supported by The Osaka Foundation for Promotion of Clinical Immunology.

We thank Dr. Takachika Hiroi and Kohtaro Fujihashi for helpful discussion, and Dr. Michael Dee Gunn and Dr. Hideki Nakano (NIHES, NC, USA) for excellent criticism of the manuscript.

## References

- [1] D. Carbone, Smoking and cancer, *Am. J. Med.* 93 (1992) 135–175.
- [2] L. Erhardt, Cigarette smoking: an undertreated risk factor for cardiovascular disease, *Atherosclerosis* 205 (2009) 23–32.
- [3] M.I. Ryder, The influence of smoking on host responses in periodontal infections, *Periodontol* 2000 (43) (2007) 267–277.
- [4] G.G. Brusselle, G.F. Joos, K.R. Bracke, New insights into the immunology of chronic obstructive pulmonary disease, *Lancet* 378 (2011) 1015–1026.
- [5] M.R. Stämpfli, G.P. Anderson, How cigarette smoke skews immune responses to promote infection, lung disease and cancer, *Nat. Rev. Immunol.* 9 (2009) 377–384.
- [6] P.G. Holt, D. Keast, Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals, *Bacteriol. Rev.* 41 (1977) 205–216.
- [7] Y. Geng, S.M. Savage, S. Razani-Boroujerdi, M.L. Sopori, Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy, *J. Immunol.* 156 (1996) 2384–2390.
- [8] A.D. Maus, E.F. Pereira, P.I. Karachunski, R.M. Horton, D. Navaneetham, K. Macklin, W.S. Cortes, E.X. Albuquerque, B.M. Conti-Fine, Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors, *Mol. Pharmacol.* 54 (1998) 779–788.
- [9] K. Kawashima, T. Fujii, Extraneuronal cholinergic system in lymphocytes, *Pharmacol. Ther.* 86 (2000) 29–48.
- [10] H.S. Sekhon, Y. Jia, R. Raab, A. Kuryatov, J.F. Pankow, J.A. Whitsett, J. Lindstrom, E.R. Spindel, Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys, *J. Clin. Invest.* 103 (1999) 637–647.
- [11] H. Wang, M. Yu, M. Ochani, C.A. Amella, M. Tanovic, S. Susarla, J.H. Li, H. Wang, H. Yang, L. Ulloa, Y. Al-Abed, C.J. Czura, K.J. Tracey, Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation, *Nature* 421 (2003) 384–388.
- [12] M.R. Blanchet, A. Langlois, E. Israel-Assayag, M.J. Beaulieu, C. Ferland, M. Lavolette, Y. Cormier, Modulation of eosinophil activation in vitro by a nicotinic receptor agonist, *J. Leukoc. Biol.* 81 (2007) 1245–1251.
- [13] H. Wang, H. Liao, M. Ochani, M. Justiniani, X. Lin, L. Yang, Y. Al-Abed, H. Wang, C. Metz, E.J. Miller, K.J. Tracey, L. Ulloa, Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis, *Nat. Med.* 10 (2004) 1216–1221.
- [14] D. Hoffmann, J.D. Adams, Carcinogenic tobacco-specific N-nitrosamines in snuff and in the saliva of snuff dippers, *Cancer Res.* 41 (1981) 4305–4308.
- [15] T. Sato, T. Abe, N. Nakamoto, Y. Tomaru, N. Koshikiya, J. Nojima, S. Kokabu, Y. Sakata, A. Kobayashi, T. Yoda, Nicotine induces cell proliferation in association with cyclin D1 up-regulation and inhibits cell differentiation in association with p53 regulation in a murine pre-osteoblastic cell line, *Biochem. Biophys. Res. Commun.* 377 (2008) 126–130.
- [16] C. Feyerabend, T. Higenbottam, M.A. Russell, Nicotine concentrations in urine and saliva of smokers and non-smokers, *Br. Med. J. (Clin. Res. Ed.)* 284 (1982) 1002–1004.
- [17] J. Banachereau, R.M. Steinman, Dendritic cells and the control of immunity, *Nature* 392 (1998) 245–252.
- [18] S. Akira, K. Takeda, T. Kaisho, Toll-like receptors: critical proteins linking innate and acquired immunity, *Nat. Immunol.* 2 (2001) 675–680.
- [19] T.A. Wynn, T(H)-17: a giant step from T(H)1 and T(H)2, *Nat. Immunol.* 6 (2005) 1069–1070.
- [20] K. Shortman, Y.J. Liu, Mouse and human dendritic cell subtypes, *Nat. Rev. Immunol.* 2 (2002) 151–161.

- [21] Y. Belkaid, G. Oldenhove, Tuning microenvironments: induction of regulatory T cells by dendritic cells, *Immunity* 29 (2008) 362–371.
- [22] M. Rimoldi, M. Chieppa, V. Salucci, F. Avogadri, A. Sonzogni, G.M. Sampietro, A. Nespoli, G. Viale, P. Allavena, M. Rescigno, Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells, *Nat. Immunol.* 6 (2005) 507–514.
- [23] R. Vassallo, K. Tamada, J.S. Lau, P.R. Kroening, L. Chen, Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming, *J. Immunol.* 175 (2005) 2684–2691.
- [24] M. Nouri-Shirazi, E. Guinet, Evidence for the immunosuppressive role of nicotine on human dendritic cell functions, *Immunology* 109 (2003) 365–373.
- [25] A. Aicher, C. Heeschen, M. Mohaupt, J.P. Cooke, A.M. Zeiher, S. Dimmeler, Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions, *Circulation* 107 (2003) 604–611.
- [26] T.M. Willson, M.H. Lambert, S.A. Kliewer, Peroxisome proliferator-activated receptor gamma and metabolic disease, *Annu. Rev. Biochem.* 70 (2001) 341–367.
- [27] F. Picard, J. Auwerx, PPAR(gamma) and glucose homeostasis, *Annu. Rev. Nutr.* 22 (2002) 167–197.
- [28] C. Jiang, A.T. Ting, B. Seed, PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, *Nature* 391 (1998) 82–86.
- [29] M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, C.K. Glass, The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation, *Nature* 391 (1998) 79–82.
- [30] J.I. Odegaard, R.R. Ricardo-Gonzalez, M.H. Goforth, C.R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, D. Vats, F. Brombacher, A.W. Ferrante, A. Chawla, Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance, *Nature* 447 (2007) 1116–1120.
- [31] L. Klotz, I. Dani, F. Edenhofer, L. Nolden, B. Evert, B. Paul, W. Kolanus, T. Klockgether, P. Knolle, L. Diehl, Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4<sup>+</sup> T cell anergy, *J. Immunol.* 178 (2007) 2122–2131.
- [32] P. Gosset, A.S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, J. Pestel, A.B. Tonnel, F. Trottein, Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells, *Eur. J. Immunol.* 31 (2001) 2857–2865.
- [33] I. Szatmari, A. Pap, R. Ruhl, J.X. Ma, P.A. Illarionov, G.S. Besra, E. Rajnavolgyi, B. Dezso, L. Nagy, PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells, *J. Exp. Med.* 203 (2006) 2351–2362.
- [34] A. Nencioni, F. Grunebach, A. Zobywalski, C. Denzlinger, W. Brugger, P. Brossart, Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma, *J. Immunol.* 169 (2002) 1228–1235.
- [35] M. Cernadas, J. Lu, G. Watts, M.B. Brenner, CD1a expression defines an interleukin-12 producing population of human dendritic cells, *Clin. Exp. Immunol.* 155 (2009) 523–533.
- [36] P. Gogolak, B. Rethi, I. Szatmari, A. Lanyi, B. Dezso, L. Nagy, E. Rajnavolgyi, Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma, *Blood* 109 (2007) 643–652.
- [37] P.R. Kroening, T.W. Barnes, L. Pease, A. Limper, H. Kita, R. Vassallo, Cigarette smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways, *J. Immunol.* 181 (2008) 1536–1547.
- [38] E. Mortaz, Z. Lazar, L. Koenderman, A.D. Kraneveld, F.P. Nijkamp, G. Folkerts, Cigarette smoke attenuates the production of cytokines by human plasmacytoid dendritic cells and enhances the release of IL-8 in response to TLR-9 stimulation, *Respir. Res.* 10 (2009) 47.
- [39] E. Mortaz, A.D. Kraneveld, J.J. Smit, M. Kool, B.N. Lambrecht, S.L. Kunkel, N.W. Lukacs, F.P. Nijkamp, G. Folkerts, Effect of cigarette smoke extract on dendritic cells and their impact on T-cell proliferation, *PLoS ONE* 4 (2009) e4946.
- [40] M. Brigl, M.B. Brenner, CD1: antigen presentation and T cell function, *Annu. Rev. Immunol.* 22 (2004) 817–890.
- [41] T. Ito, M. Inaba, K. Inaba, J. Toki, S. Sogo, T. Iguchi, Y. Adachi, K. Yamaguchi, R. Amakawa, J. Valladeau, S. Saeland, S. Fukuhara, S. Ikehara, A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells, *J. Immunol.* 163 (1999) 1409–1419.
- [42] C.Q. Xia, K.J. Kao, Heparin induces differentiation of CD1a+ dendritic cells from monocytes: phenotypic and functional characterization, *J. Immunol.* 168 (2002) 1131–1138.
- [43] G. Castellano, A.M. Woltman, N. Schlagwein, W. Xu, F.P. Schem, M.R. Daha, C. van Kooten, Immune modulation of human dendritic cells by complement, *Eur. J. Immunol.* 37 (2007) 2803–2811.
- [44] K. Laudanski, A. De, C. Miller-Graziano, Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells, *Eur. J. Immunol.* 37 (2007) 2812–2824.
- [45] E.A. Laborde, S. Vanzulli, M. Beigier-Bompadre, M.A. Isturiz, R.A. Ruggiero, M.G. Fourcade, A.C. Catalan Pellet, S. Sozzani, M. Vulcano, Immune complexes inhibit differentiation, maturation, and function of human monocyte-derived dendritic cells, *J. Immunol.* 179 (2007) 673–681.
- [46] A.H. Sharpe, E.J. Wherry, R. Ahmed, G.J. Freeman, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, *Nat. Immunol.* 8 (2007) 239–245.
- [47] C. Chen, Q.X. Qu, J.A. Huang, Y.B. Zhu, Y. Ge, Q. Wang, X.G. Zhang, Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells, *Immunobiology* 212 (2007) 159–165.
- [48] N. Selenko-Gebauer, O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W.F. Pickl, H. Stockinger, W. Knapp, J. Stockl, B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy, *J. Immunol.* 170 (2003) 3637–3644.
- [49] J.V. Ravetch, L.L. Lanier, Immune inhibitory receptors, *Science* 290 (2000) 84–89.
- [50] C.C. Chang, R. Ciubotariu, J.S. Manavalan, J. Yuan, A.I. Colovai, F. Piazza, S. Lederman, M. Colonna, R. Cortesini, R. Dalla-Favera, N. Suci-Foca, Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4, *Nat. Immunol.* 3 (2002) 237–243.
- [51] C. Faveeuw, S. Fougeray, V. Angeli, J. Fontaine, G. Chinetti, P. Gosset, P. Delerive, C. Maliszewski, M. Capron, B. Staels, M. Moser, F. Trottein, Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells, *FEBS Lett.* 486 (2000) 261–266.
- [52] S. Appel, V. Mirakaj, A. Bringmann, M.M. Weck, F. Grunebach, P. Brossart, PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways, *Blood* 106 (2005) 3888–3894.
- [53] R. Hontecillas, J. Bassaganya-Riera, Peroxisome proliferator-activated receptor gamma is required for regulatory CD4<sup>+</sup> T cell-mediated protection against colitis, *J. Immunol.* 178 (2007) 2940–2949.
- [54] E.A. Wohlfert, F.C. Nichols, E. Nevis, R.B. Clark, Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms, *J. Immunol.* 178 (2007) 4129–4135.
- [55] L. Klotz, S. Hucke, D. Thimm, S. Classen, A. Gaarz, J. Schultze, F. Edenhofer, C. Kurts, T. Klockgether, A. Limmer, P. Knolle, S. Burgdorf, Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1, *J. Immunol.* 183 (2009) 129–136.
- [56] P.J. Barnes, Chronic obstructive pulmonary disease, *N. Engl. J. Med.* 343 (2000) 269–280.
- [57] C. Heeschen, J.J. Jang, M. Weis, A. Pathak, S. Kaji, R.S. Hu, P.S. Tsao, F.L. Johnson, J.P. Cooke, Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis, *Nat. Med.* 7 (2001) 833–839.
- [58] K.G. Saag, J.R. Cerhan, S. Kolluri, K. Ohashi, G.W. Hunninghake, D.A. Schwartz, Cigarette smoking and rheumatoid arthritis severity, *Ann. Rheum. Dis.* 56 (1997) 463–469.
- [59] M.F. Mian, N.M. Lauzon, M.R. Stampfli, K.L. Mossman, A.A. Ashkar, Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke, *J. Leukoc. Biol.* 83 (2008) 774–784.
- [60] T.E. King Jr., D. Savici, P.A. Campbell, Phagocytosis and killing of *Listeria monocytogenes* by alveolar macrophages: smokers versus nonsmokers, *J. Infect. Dis.* 158 (1988) 1309–1316.
- [61] A.D. Harries, A. Baird, J. Rhodes, Non-smoking: a feature of ulcerative colitis, *Br. Med. J. (Clin. Res. Ed.)* 284 (1982) 706.
- [62] B.M. Calkins, A meta-analysis of the role of smoking in inflammatory bowel disease, *Dig. Dis. Sci.* 34 (1989) 1841–1854.
- [63] L. Dubuquoy, E.A. Jansson, S. Deeb, S. Rakotobe, M. Karoui, J.F. Colombel, J. Auwerx, S. Pettersson, P. Desreumaux, Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis, *Gastroenterology* 124 (2003) 1265–1276.

# Adiponectin regulates functions of gingival fibroblasts and periodontal ligament cells

T. Iwayama, M. Yanagita, K. Mori, K. Sawada, M. Ozasa, M. Kubota, K. Miki, Y. Kojima, M. Takedachi, M. Kitamura, Y. Shimabukuro, T. Hashikawa, S. Murakami

Division of Oral Biology and Disease Control, Department of Periodontology, Osaka University Graduate School of Dentistry, Yamadaoka, Suita, Osaka, Japan

Iwayama T, Yanagita M, Mori K, Sawada K, Ozasa M, Kubota M, Miki K, Kojima Y, Takedachi M, Kitamura M, Shimabukuro Y, Hashikawa T, Murakami S.

*Adiponectin regulates functions of gingival fibroblasts and periodontal ligament cells.*

*J Periodont Res* 2012; doi: 10.1111/j.1600-0765.2012.01467.x. © 2012 John Wiley & Sons A/S

**Background and Objective:** Adiponectin is a cytokine constitutively produced by adipocytes and exhibits multiple biological functions by targeting various cell types. However, the effects of adiponectin on primary gingival fibroblasts and periodontal ligament cells are still unexplored. Therefore, we investigated the effects of adiponectin on gingival fibroblasts and periodontal ligament cells.

**Material and Methods:** The expression of adiponectin receptors (AdipoR1 and AdipoR2) on human gingival fibroblasts (HGFs), mouse gingival fibroblasts (MGFs) and human periodontal ligament (HPDL) cells was examined using RT-PCR and western blotting. HGFs and MGFs were stimulated with interleukin (IL)-1 $\beta$  in the presence or absence of adiponectin, and the expression of IL-6 and IL-8 at both mRNA and protein levels was measured by real-time PCR and ELISA, respectively. Furthermore, small interfering RNAs (siRNAs) in MGFs were used to knock down the expression of mouse AdipoR1 and AdipoR2. The effects of adiponectin on the expression of alkaline phosphatase (*ALP*) and runt-related transcription factor 2 (*Runx2*) genes were evaluated by real-time PCR. Mineralized nodule formation of adiponectin-treated HPDL cells was revealed by Alizarin Red staining.

**Results:** AdipoR1 and AdipoR2 were expressed constitutively in HGFs, MGFs and HPDL cells. Adiponectin decreased the expression of IL-6 and IL-8 in IL-1 $\beta$ -stimulated HGFs and MGFs. AdipoR1 siRNA in MGFs revealed that the effect of adiponectin on reduction of IL-6 expression was potentially mediated via AdipoR1. Adiponectin-treated HPDL cells promoted the expression of *ALP* and *Runx2* mRNAs and up-regulated ALP activity. Furthermore, adiponectin enhanced mineralized nodule formation of HPDL cells.

**Conclusion:** Our observations demonstrate that adiponectin exerts anti-inflammatory effects on HGFs and MGFs, and promotes the activities of osteoblastogenesis of HPDL cells. We conclude that adiponectin has potent beneficial functions to maintain the homeostasis of periodontal health, improve periodontal lesions, and contribute to wound healing and tissue regeneration.

Shinya Murakami, PhD, DDS, Division of Oral Biology and Disease Control, Department of Periodontology, Osaka University Graduate School of Dentistry, Yamadaoka 1-8, Suita, Osaka 565-0871, Japan  
Tel: +81 6 6879 2930  
Fax: +81 6 6879 2934  
e-mail: ipshinya@dent.osaka-u.ac.jp

Key words: adiponectin; gingival fibroblasts; inflammation; periodontal ligament cells

Accepted for publication January 11, 2012

Periodontal disease is a chronic inflammatory disease initiated by the biofilm of periodontopathic bacteria, leading to the destruction of peri-

odontal tissues. Periodontal disease can be exacerbated by many factors;

for example, systemic diseases, such as diabetes, osteoporosis and immunodeficiency diseases, have been shown to result in an increased risk for periodontal disease (1). Interestingly, recent epidemiologic studies have suggested that obesity is also a risk factor for periodontitis (2,3). Obesity, which induces insulin resistance following systemic chronic inflammation (4), is one of the leading causes of type 2 diabetes, which is closely associated with periodontal diseases. Thus, it is possible that obesity and metabolic syndrome could be risk factors for the progression of periodontal diseases; however, the precise mechanism of how obesity results in the destruction of periodontal tissue remains unclear.

Adipokines, secreted by adipose tissue, can influence insulin resistance, inflammation and the cardiovascular system (5). Adiponectin – an adipokine – circulates in high concentrations in plasma (6). Two adiponectin receptors (AdipoRs) have been reported to be expressed on various tissues and cells (7). Importantly, hypo-adiponectinemia has been observed in patients with type 2 diabetes mellitus, obesity and coronary artery disease (8,9). Physiological concentrations of adiponectin suppressed tumor necrosis factor- $\alpha$ -induced inflammatory responses in human endothelial cells and macrophages (10). Recent studies have revealed that the concentrations of adiponectin in serum of patients with severe periodontitis are lower than those in serum from healthy subjects (11,12). Periodontal treatment has also been shown to increase the levels of adiponectin in chronic periodontitis (13). Interestingly, Yamaguchi *et al.* (14) reported that the levels of expression of AdipoRs were decreased in sites of severe periodontitis. These data suggest that adiponectin is involved in the homeostasis of periodontal tissues and may modulate inflammatory responses at periodontal lesions.

In recent years, adiponectin and AdipoRs have been reported to be expressed in osteoblasts (15,16), suggesting that adiponectin may be involved not only in anti-inflammatory functions but also in bone metabolism. Among periodontal tissues, periodon-

tal ligament (PDL) cells have the potential to regulate neogenesis of alveolar bone and cementum and play important roles in events of wound healing and regeneration following periodontal tissue breakdown caused by progression of periodontal diseases. Considering the multifunctional role of adiponectin, adiponectin may affect the functional characteristics of PDL cells, which can differentiate into mineralized tissue-forming cells such as osteoblasts and cementoblasts (17).

In this study we investigated the anti-inflammatory effect of adiponectin on human gingival fibroblasts (HGFs) and mouse gingival fibroblasts (MGFs). In addition, we examined the physiological effect of adiponectin on cytodifferentiation of human PDL (HPDL) cells. The results showed that adiponectin suppressed proinflammatory cytokines induced by interleukin (IL)-1 $\beta$  stimulation, possibly via AdipoR1. Furthermore, adiponectin promoted the differentiation and mineralization of HPDL cells.

## Material and methods

### Reagents

Recombinant human and mouse IL-1 $\beta$ , adiponectin and normal rabbit IgG were obtained from R&D Systems (Minneapolis, MN, USA). Anti-adipoR1 IgG was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Alpha Diagnostic Intl. Inc. (San Antonio, TX, USA).

### Cells

Before participating in this study, all human subjects provided informed consent according to a protocol that was reviewed and approved by the Institutional Review Board of the Osaka University Graduate School of Dentistry. HGFs were obtained from biopsies of healthy gingiva taken from healthy volunteers, as previously described (18). HGFs were used for experiments at passages 4–10. MGFs were isolated from healthy gingival tissue of the first premolar teeth of BALB/c mice. When the cells that grew out from the explants reached

confluence, they were separated by treatment with 0.53 mM EDTA containing 0.05% trypsin, collected by centrifugation and cultured on plastic culture dishes containing standard medium (standard medium is  $\alpha$ -minimal essential medium containing 10% fetal calf serum) until they reached confluence. After 12 passages, the clonal MGF cell line was established using the limiting-dilution method. HPDL cells were isolated and maintained as described previously (19,20). For the induction of cytodifferentiation, HPDL cells were cultured in  $\alpha$ -minimal essential medium ( $\alpha$ -MEM) containing 10% fetal calf serum, 10 mM  $\beta$ -glycerophosphate and 50  $\mu$ g/mL of ascorbic acid [(calcification-inducing medium (C-Med)]. C-Med was replaced every 3 d.

### RT-PCR

Total RNA was isolated from HGFs, HPDL cells and MGFs using an RNA-Bee kit (TEL-TEST, Inc., Friendswood, TX, USA) according to the manufacturer's instructions. cDNA was synthesized and amplified using PCR, as described previously (18). Oligonucleotide PCR primers specific for adiponectin and AdipoRs were synthesized by Clontech (Palo Alto, CA, USA). The sequences of the primers are shown in Table 1. Hypoxanthine phosphoribosyltransferase (HPRT) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as housekeeping genes.

### Western blot analysis

HGFs, HPDL cells and MGFs were lysed in RIPA buffer [25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1% sodium deoxycholate, 0.1% SDS, 10 mM Na<sub>3</sub>VO<sub>4</sub> and 10  $\mu$ g/mL each of aprotinin and leupeptin]. The proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were incubated with 10% bovine serum albumin for 1 h and subsequently with rabbit polyclonal anti-adiponectin Ig (Alpha Diagnostic International inc.) or goat polyclonal anti-AdipoR Ig (Santa Cruz Biotechnology) for 1 h at

Table 1. Primers used for RT-PCR

Gene	Sequence	
Human	Forward	5'-CGA GAT GTG ATG AAG GAG ATG GG-3'
<i>HPRT1</i>	Reverse	5'-GCC TGA CCA AGG AAA GCA AAG TC-3'
Human	Forward	5'-CAA ACA GCC CCA AAG TCA AT-3'
<i>Adiponectin</i>	Reverse	5'-TCT CAG GTG AGG TGG GAA AC-3'
Human	Forward	5'-AAA CTG GCA ACA TCT GGA CC-3'
<i>AdipoR1</i>	Reverse	5'-GCT GTG GGG AGC AGT AGA AG-3'
Human	Forward	5'-ACA GGC AAC ATT TGG ACA CA-3'
<i>AdipoR2</i>	Reverse	5'-CCA AGG AAC AAA ACT TCC CA-3'
Mouse	Forward	5'-AGG TTG TCT CCT GCG ACT TC-3'
<i>GAPDH</i>	Reverse	5'-CTT GCT CAG TGT CCT TGC TG-3'
Mouse	Forward	5'-ATC TGA CGA CAC CAA AAG GG-3'
<i>Adiponectin</i>	Reverse	5'-TCT CCA GGA GTG CCA TCT CT-3'
Mouse	Forward	5'-TGC CCT CCT TTC GGG CTT GC-3'
<i>AdipoR1</i>	Reverse	5'-GCC TTG ACA AAG CCC TCA GCG ATA G-3'
Mouse	Forward	5'-TCT TCC TGT GCC TGG GGA TCT T-3'
<i>AdipoR2</i>	Reverse	5'-CCC GAT ACT GAG GGG TGG CAA A-3'

*AdipoR1*, adiponectin receptor 1; *AdipoR2*, adiponectin receptor 2; *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase; *HPRT1*, hypoxanthine phosphoribosyltransferase-1.

room temperature and appropriate horseradish peroxidase-conjugated secondary antibody. Immune complexes were detected using an enhanced chemiluminescence kit (Thermo Fisher Scientific, Waltham, MA, USA).

### Real-time PCR

HGFs and MGFs were seeded in a six-well plate at a density of  $3 \times 10^5$  cells and  $1.2 \times 10^6$  cells/well, respectively. Cells were grown to confluence in standard medium. Following 18 h of preincubation in the presence or absence of adiponectin, cells were treated with or without 0.1 ng/mL of IL-1 $\beta$ , then total RNA was isolated and precipitated. cDNA was synthesized and mixed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and gene-specific primers (Takara Bio, Shiga, Japan). Real-time PCR was performed using a 7300 Fast Real-Time PCR System (Applied Biosystems). The sequences of the primers are shown in Table 2. *HPRT* and *GAPDH* served as housekeeping genes.

### Measurement of inflammatory cytokines in culture supernatants

HGFs and MGFs were seeded in a 12-well plate at a density of  $1.8 \times 10^5$  and  $7.2 \times 10^5$  cells, respectively, and grown to confluence in standard medium. Following 18 h of preincubation

with or without adiponectin, cells were treated with or without 0.5 ng/mL of IL-1 $\beta$ . In some experiments, cells were pretreated for 1 h with anti-adiponectin Ig. At the end of the incubation periods, the supernatants were collected and the levels of IL-6 and IL-8 (HGFs only) protein were measured using ELISA kits (R&D Systems) according to the manufacturer's instructions.

### RNA interference

Small interfering RNA (siRNA) was used to knock down the expression of mouse *AdipoR1* and *AdipoR2*. The *AdipoR1* and *AdipoR2* siRNAs, and a

negative-control siRNA (Silencer Select Negative Control #1 siRNA), were synthesized by Applied Biosystems. Silencer 1 Negative Control #1 siRNA was designed to have no significant sequence similarity to mouse, rat or human transcript sequences. MGFs were placed on a six-well culture dish. Twenty-four hours after incubation, MGFs, at 40–50% confluence, were transfected with siRNA *AdipoR1*, siRNA *AdipoR2* or negative-control siRNA. The cells were transfected with 200 pmol of siRNA and negative-control siRNA using Lipofectamine 2000 (Invitrogen Corp, Carlsbad, CA, USA) according to the

Table 2. Primers used for real-time PCR

Gene	Sequence
Human	Forward
<i>HPRT1</i>	Reverse
Human	Forward
<i>IL6</i>	Reverse
Human	Forward
<i>IL8</i>	Reverse
Human	Forward
<i>ALP</i>	Reverse
Human	Forward
<i>RUNX2</i>	Reverse
Mouse	Forward
<i>GAPDH</i>	Reverse
Mouse	Forward
<i>IL6</i>	Reverse

*ALP*, alkaline phosphatase; *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase; *HPRT1*, hypoxanthine phosphoribosyltransferase-1; *IL6*, interleukin-6; *IL8*, interleukin-8; *RUNX2*, runt-related transcription factor 2.

manufacturer's instructions. The cells were then analyzed using real-time PCR.

#### Determination of alkaline phosphatase activity, and staining with Alizarin Red

Alkaline phosphatase (ALP) activity was assessed according to the procedure described previously (20,21). Histochemical analysis of calcified nodules was performed using the Alizarin Red staining method (20,22). The density of calcified nodules in each well was calculated using the WinRoof software program (Mitani Corporation, Fukui, Japan).

#### Statistical analysis

The results were analyzed for statistical significance using the Student's *t*-test. Differences were considered significant at  $p < 0.05$ .

## Results

#### Expression of AdipoR1 and AdipoR2, but not adiponectin, was detected in HGFs, HPDL cells and MGFs

To examine the expression of adiponectin and its receptors (AdipoR1 and AdipoR2) and mRNA and protein in HGFs, HPDL cells and MGFs, we performed RT-PCR amplification and western blotting. As shown in Fig. 1A and 1B, mRNA transcripts and protein for AdipoR1 and AdipoR2, but not for adiponectin, were detected in all cell types investigated.

#### Adiponectin reduced the expression of proinflammatory cytokines in IL-1 $\beta$ -stimulated HGFs

To the effect of adiponectin on the expression of proinflammatory cytokines in IL-1 $\beta$ -stimulated HGFs, HGFs were pretreated with adiponectin for 18 h before 2.5 h of stimulation with IL-1 $\beta$ , whereupon real-time PCR was performed. As shown in Fig. 2A, adiponectin significantly reduced the expression of *IL6* and *IL8* mRNAs. For assessment of IL-6 and IL-8 pro-




Fig. 1. Expression of adiponectin (ApN), adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). (A) Expression of *ApN*, *AdipoR1* and *AdipoR2* genes in human gingival fibroblasts (HGFs), human periodontal ligament (HPDL) cells and mouse gingival fibroblasts (MGFs) was examined by RT-PCR. (B) Expression of AdipoR1 and AdipoR2 proteins in HGFs, HPDL cells and MGFs was detected using western blotting. The data represent one of three independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyltransferase.

duction, adiponectin-pretreated HGFs were stimulated with 0.5 ng/mL of IL-1 $\beta$ , harvested after 12 h and then assayed using ELISA. Adiponectin also reduced the production of IL-6 protein and IL-8 protein (Fig. 2B).


#### AdipoR1 knockdown abrogated the adiponectin-induced reduction of IL-6 expression in MGFs

To examine the effect of adiponectin on the expression of IL-6 in IL-1 $\beta$ -stimulated MGFs, MGFs were pretreated with adiponectin for 18 h before stimulation with IL-1 $\beta$  for 2.5 h, whereupon real-time PCR was performed. As shown in Fig. 3A, adiponectin significantly reduced the expression of *IL6* mRNA. To assess the production of IL-6 protein, adiponectin-pretreated MGF were stimulated with 0.5 ng/mL of IL-1 $\beta$ , harvested after 12 h and then assayed using ELISA. Adiponectin also reduced the production of IL-6 protein (Fig. 3B). To elucidate the effect of adiponectin via AdipoRs, siRNA was used to block the expression of *AdipoR1* and *AdipoR2* mRNAs. As shown

in Fig. 4A and 4B, real-time PCR revealed that treatment with siRNA-AdipoR1 and siRNA-AdipoR2 significantly reduced the expression of AdipoR1 and AdipoR2 in MGFs compared with negative-control siRNA (Fig. 4A and 4B). Whereas IL-1 $\beta$ -induced expression of IL-6 in MGF treated with negative-control siRNA was significantly suppressed by adiponectin treatment, these suppressive effects were attenuated in MGFs treated with siRNA for AdipoR1 (Fig. 4C). By contrast, treatment with siRNA for AdipoR2 did not suppress IL-1 $\beta$ -induced expression of IL-6 by adiponectin (Fig. 4D). These results suggest that adiponectin reduces IL-6 expression in MGFs possibly via AdipoR1.

#### Anti-AdipoR1 Ig attenuated the adiponectin-induced reduction of IL-6 expression in HGF

To elucidate the effect of adiponectin via AdipoR1, HGFs were pretreated with control antibodies or with two types of anti-AdipoR1 polyclonal Igs and then stimulated with IL-1 $\beta$  in the presence or absence of adiponectin.



**Fig. 2.** Adiponectin reduced interleukin (IL)-1 $\beta$ -induced production of IL-6 and IL-8 in human gingival fibroblasts (HGFs). (A) Expression of *IL6* and *IL8* genes in HGFs was examined using real-time PCR. HGFs were pretreated with adiponectin (ApN; 5  $\mu$ g/mL) for 18 h, stimulated with IL-1 $\beta$  (0.1 ng/mL) for 2.5 h and then total RNA was isolated. (B) The levels of IL-6 and IL-8 protein in HGF cultured condition medium were measured using ELISA. HGFs were pretreated with adiponectin (ApN; 10  $\mu$ g/mL) for 18 h and stimulated for 12 h with IL-1 $\beta$  (0.5 ng/mL). Data are the mean  $\pm$  standard deviation of triplicate determinations. \* $p$  < 0.05 compared with IL-1 $\beta$ -stimulated HGF without ApN pretreatment. HPRT, hypoxanthine phosphoribosyltransferase.

After 12 h, IL-6 production in the culture supernatants was assayed using ELISA. As shown in Fig. 5, anti-AdipoR1 Igs significantly attenuated the suppression of IL-1 $\beta$ -induced IL-6 expression by adiponectin. These results suggest that adiponectin reduces IL-6 expression in the IL-1 $\beta$ -stimulated HGFs possibly via AdipoR1.


#### Adiponectin promoted the differentiation and mineralization of HPDL cells

Next, we examined whether or not adiponectin would promote the differentiation and mineralization of HPDL cells. As shown in Fig. 6A, ALP activity in HPDL cells was significantly enhanced in the presence of adiponectin. Real-time PCR revealed that adiponectin significantly enhanced the expression of *ALP* and runt-related transcription factor 2 (*Runx2*; an

important transcription factor involved in osteoblastic differentiation and mineralization) (23) genes in HPDL cells cultured with C-Med in the presence of adiponectin (Fig. 6B and 6C) compared with C-Med only. Subsequently, mineralized nodule formation by HPDL cells on day 18 was investigated. As shown in Fig. 7A and 7B, adiponectin significantly increased the intensity of Alizarin Red staining. These results suggest that adiponectin promotes the differentiation and mineralization of HPDL cells.

#### Discussion

Adiponectin is an abundant serum protein, with concentrations in the order of 3–30  $\mu$ g/mL (10). In this study, we demonstrated, for the first time, that physiological concentrations of adiponectin suppress IL-1 $\beta$ -induced IL-6 and IL-8 expression in HGFs, and IL-6 in



**Fig. 3.** Adiponectin reduced interleukin (IL)-1 $\beta$ -induced expression of IL-6 in mouse gingival fibroblasts (MGFs). (A) Expression of the *IL6* gene in MGFs was examined by real-time PCR. MGFs were pretreated with adiponectin (ApN; 20  $\mu$ g/mL) for 18 h, stimulated with IL-1 $\beta$  (0.5 ng/mL) for 2.5 h and then total RNA was isolated. (B) The level of IL-6 protein in MGF cultured condition medium was measured by ELISA. MGFs were pretreated with adiponectin (ApN; 20  $\mu$ g/mL) for 18 h and stimulated with IL-1 $\beta$  (0.5 ng/mL) for 12 h. Data are the mean  $\pm$  standard deviation of triplicate determinations. \* $p$  < 0.05 compared with IL-1 $\beta$ -stimulated MGFs without pretreatment of adiponectin. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

MGFs, at mRNA and protein levels, possibly via AdipoR1 signaling. We also showed that adiponectin enhances the differentiation and mineralization of HPDL cells. Unfortunately, however, mouse IL-8 has not yet been identified. As mouse CXCL1 is known to be the functional homolog of human IL-8, we examined the expression CXCL1 in preliminary studies (data not shown). In these studies, we found that adiponectin significantly reduced the expression of *CXCL1* mRNA. However, the expression of CXCL1 protein was not reduced by adiponectin (data not shown).

Several previous studies have reported that adiponectin is the immunomodulatory cytokine for the function of monocytes, macrophages and




Fig. 4. Silencing adiponectin receptor 1 (AdipoR1) using small interfering (si)RNA attenuated the suppression of interleukin-6 (*IL6*) gene expression in mouse gingival fibroblasts (MGFs) stimulated with IL-1 $\beta$ . (A and B) MGFs transfected with AdipoR1, AdipoR2, or negative-control siRNAs were cultured for 24 h. *AdipoR1* and *AdipoR2* mRNAs were quantified using real-time PCR. These data represent one of three independent experiments. Data are the mean  $\pm$  standard deviation of triplicate determinations (\* $p$  < 0.05). (C and D) Expression of the *IL6* gene in MGFs was examined using real-time PCR. MGFs transfected with AdipoR1, AdipoR2, or negative-control siRNAs were cultured for 24 h. The cells were seeded, pretreated with adiponectin (ApN; 20  $\mu$ g/mL) for 18 h, stimulated with IL-1 $\beta$  (0.5 ng/mL) for 2 h and then total RNA was isolated. Data are the mean  $\pm$  standard deviation of triplicate determinations. \* $p$  < 0.05 compared with IL-1 $\beta$ -stimulated MGFs without ApN pretreatment. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Lipo, lipofectamine 2000.

endothelial cells (10) and exhibits functional activity through binding to two AdipoRs. A recent systematic review concluded that there was a positive association between periodontal disease and obesity across diverse populations (3). The plasma adiponectin level in obese individuals was decreased compared with that in non-obese individuals (24). Saito *et al.* (11) previously reported that serum adiponectin levels in women with periodontitis were lower than in those with healthy gingiva, although this difference was not significant. Additionally, Yamaguchi *et al.* (14) revealed that the expression levels of AdipoRs in regions of periodontal disease were lower than in healthy gingival tissue. In mice with collagen-induced arthritis, adiponectin mitigated the severity of diseases (25). In addition, adiponectin suppressed the expression of inflammatory cytokines in stimulated rheumatoid arthritis

synovial fibroblasts (25). We found that HGFs, HPDL cells and MGFs expressed AdipoR1 and AdipoR2, but not adiponectin (Fig. 1). Additionally, we showed that suppression of AdipoR1 expression by its siRNA and anti-AdipoR1 Ig abrogated the anti-inflammatory actions of the cells, suggesting that adiponectin promoted these responses through the action of AdipoR1, at least in part on gingival fibroblasts (Figs 4 and 5).

Recent studies have demonstrated that AdipoRs are also expressed on osteoblasts (15,16,26). In the present study we showed that AdipoR1 and AdipoR2 expressed on HPDL cells and adiponectin enhanced ALP activity, expression of *ALP* and *Runx2* genes, and mineralized nodule formation in HPDL cells (Figs 6 and 7). ALP is an enzyme marker of osteoblasts and participates in mineralization (27). Runx2 has been identified as an important transcription

factor that is involved in bone formation and osteoblast differentiation (23). Thus, enhanced expression of *ALP* and *Runx2* genes, stimulated by adiponectin, were correlated with the mineralization of HPDL cells. In this study we did not directly examine the possible involvement of AdipoR1 in differentiation and mineralization of HPDL cells. However, a recent study reporting that adiponectin induced the differentiation and mineralization of osteoblastic MC3T3-E1 via AdipoR1 (26) suggests that the adiponectin-AdipoR1 pathway is also involved in the cytodifferentiation of HPDL cells. Although the functional roles of adiponectin in periodontal tissues have not been fully clarified, adiponectin should be involved in maintaining the homeostasis of periodontal tissue.

In this study, we demonstrated two functional aspects of adiponectin: the




Fig. 5. Anti-adiponectin receptor 1 (AdipoR1) Igs attenuated the suppression of interleukin (IL)-6 production in human gingival fibroblasts (HGFs) stimulated with IL-1 $\beta$ . Cells were pretreated with control antibodies or with anti-AdipoR1 Igs for 1 h, incubated with adiponectin (ApN; 10  $\mu$ g/mL) for 18 h and then stimulated with IL-1 $\beta$  (0.5 ng/mL) for 12 h. The levels of IL-6 protein in HGF cultured condition medium were measured using ELISA. Data are the mean  $\pm$  standard deviation of triplicate determinations. Normalized data are shown as a percentage of the value in HGFs pretreated with the respective antibodies in the absence of ApN. \* $p$  < 0.05 compared with control antibody-pretreated HGFs in the presence of ApN.

first was an anti-inflammatory effect on gingival fibroblasts and the second was enhancement of cytodifferentiation in HPDL cells. Although we did not perform studies to clarify the signal pathway initiated following the activation of AdipoR1, accumulating evidence suggests that adiponectin increases the activities of sirtuin1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK; 10). SIRT1 is an NAD<sup>+</sup>-dependent deacetylase that interacts with and deacetylates p65 of nuclear factor- $\kappa$ B and subsequently inhibits the expression of inflammatory genes (28). Adiponectin has been shown to increase the levels of SIRT1 protein and to suppress lipopolysaccharide (LPS)-stimulated tumor necrosis factor- $\alpha$  production in Kupffer cells (29). AMPK is a heterotrimeric serine kinase responsive to a variety of cellular stimuli. In osteoblastic cells, AMPK is




Fig. 6. Adiponectin promoted the differentiation of human periodontal ligament (HPDL) cells. (A) HPDL cells were cultured in calcification-induced medium (C-Med) in the presence or absence of adiponectin (ApN; 10  $\mu$ g/mL) for the indicated periods of time, then alkaline phosphatase (ALP) activity during the cytodifferentiation of HPDL cells was measured. Data are the mean  $\pm$  standard deviation of triplicate determinations. \* $p$  < 0.05 compared with HPDL cells cultured in C-Med in the absence of ApN. (B and C) Real-time PCR was performed to determine the expression of cytodifferentiation- and mineralization-related genes, such as *ALP* (B) and runt-related transcription factor 2 (*RUNX2*) (C). HPDL cells were cultured in C-Med in the presence or absence of adiponectin (ApN; 10  $\mu$ g/mL) for the indicated periods of time. Data are the mean  $\pm$  standard deviation of triplicate determinations. \* $p$  < 0.05 compared with HPDL cells cultured in C-Med in the absence of adiponectin. HPRT, hypoxanthine phosphoribosyltransferase.




Fig. 7. Adiponectin promoted the mineralization of human periodontal ligament (HPDL) cells. (A) Mineralized nodule formation in HPDLs was detected by staining the cells with Alizarin Red after 18 d of culture in calcification-induced medium (C-Med) in the presence or absence of adiponectin (ApN; 10 µg/mL). (B) The relative expression value of Alizarin Red staining is shown in (A) and was quantified and normalized to Alizarin Red staining without C-Med. The data represent one of three independent experiments. \* $p < 0.05$  compared with C-Med only.

stimulated via AdipoR1 and induces the production of bone morphogenetic protein-2, stimulating cells to differentiate into calcified (26,30). Further studies are necessary to clarify the involvement of the SIRT1 and AMPK signaling pathways in the action of adiponectin on both gingival fibroblasts and HPDL cells.

In summary, the results of the present study suggest that adiponectin may have a therapeutically beneficial effect on the control of anti-inflammatory responses and treatment of periodontal diseases. Topical application of recombinant adiponectin during periodontal surgery may improve wound healing and regeneration at the periodontal disease site. Further studies are still required to demonstrate this therapeutic effect.

### Acknowledgements

This study was supported by Grants-in-Aid from the Japan Society for the Promotion of Science (19592386, 20390530, 21592623, 23593057 and 23249086).

### References

- Garcia RI, Henshaw MM, Krall EA. Relationship between periodontal disease and systemic health. *Periodontol* 2000;25:21–36.

- Saito T, Shimazaki Y, Sakamoto M. Obesity and periodontitis. *N Engl J Med* 1998;339:482–483.
- Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. *J Periodontol* 2010;81:1708–1724.
- Kopelman PG. Obesity as a medical problem. *Nature* 2000;404:635–643.
- Funahashi T, Nakamura T, Shimomura I et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern Med* 1999;38:202–206.
- Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 1995;270:26746–26749.
- Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 2003;423:762–769.
- Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 1999;100:2473–2476.
- Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. *Diabetes* 2002;51:2968–2974.
- Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011;11:85–97.
- Saito T, Yamaguchi N, Shimazaki Y et al. Serum levels of resistin and adiponectin in women with periodontitis: the Hisayama study. *J Dent Res* 2008;87:319–322.

- Furugen R, Hayashida H, Yamaguchi N et al. The relationship between periodontal condition and serum levels of resistin and adiponectin in elderly Japanese. *J Periodontol Res* 2008;43:556–562.
- Kardeşler L, Buduneli N, Cetinkalp S, Kinane DF. Adipokines and inflammatory mediators after initial periodontal treatment in patients with type 2 diabetes and chronic periodontitis. *J Periodontol* 2010;81:24–33.
- Yamaguchi N, Hamachi T, Kamio N et al. Expression levels of adiponectin receptors and periodontitis. *J Periodontol Res* 2010;45:296–300.
- Berner HS, Lyngstadaas SP, Spahr A et al. Adiponectin and its receptors are expressed in bone-forming cells. *Bone* 2004;35:842–849.
- Oshima K, Nampei A, Matsuda M et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. *Biochem Biophys Res Commun* 2005;331:520–526.
- Seo BM, Miura M, Gronthos S et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004;364:149–155.
- Murakami S, Hashikawa T, Saho T et al. Adenosine regulates the IL-1 beta-induced cellular functions of human gingival fibroblasts. *Int Immunol* 2001;13:1533–1540.
- Somerman MJ, Archer SY, Imm GR, Foster RA. A comparative study of human periodontal ligament cells and gingival fibroblasts in vitro. *J Dent Res* 1988;67:66–70.
- Fujihara C, Yamada S, Ozaki N et al. Role of mechanical stress-induced glutamate signaling-associated molecules in cytodifferentiation of periodontal ligament cells. *J Biol Chem* 2010;285:28286–28297.
- Bessey OA, Lowly OH, Brock MJ. A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum. *J Biol Chem* 1946;164:321–329.
- Dahl LK. A simple and sensitive histochemical method for calcium. *Proc Soc Exp Biol Med* 1952;80:474–479.
- Yang S, Wei D, Wang D, Phimpilai M, Krebsbach PH, Franceschi RT. In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation. *J Bone Miner Res* 2003;18:705–715.
- Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 1999;257:79–83.
- Lee SW, Kim JH, Park MC, Park YB, Lee SK. Adiponectin mitigates the severity of arthritis in mice with collagen-induced

- arthritis. *Scand J Rheumatol* 2008;**37**:260–268.
26. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. *BMC Cell Biol* 2007;**8**:51.
  27. Majeska RJ, Wuthier RE. Studies on matrix vesicles isolated from chick epiphyseal cartilage. Association of pyrophosphatase and ATPase activities with alkaline phosphatase. *Biochim Biophys Acta* 1975;**391**:51–60.
  28. Yang SR, Wright J, Bouter M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. *Am J Physiol Lung Cell Mol Physiol* 2007;**292**:L567–L576.
  29. Shen Z, Ajmo JM, Rogers CQ *et al.* Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. *Am J Physiol Gastrointest Liver Physiol* 2009;**296**:G1047–G1053.
  30. Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH. Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. *J Cell Physiol* 2010;**224**:475–483.

CASE REPORT

Open Access

# Periodontal disease in a patient with Prader-Willi syndrome: a case report

Manabu Yanagita, Hiroyuki Hirano, Mariko Kobashi, Takenori Nozaki, Satoru Yamada, Masahiro Kitamura and Shinya Murakami\*

## Abstract

**Introduction:** Prader-Willi syndrome is a complex genetic disease caused by lack of expression of paternally inherited genes on chromosome 15q11-q13. The prevalence of Prader-Willi syndrome is estimated to be one in 10,000 to 25,000. However, descriptions of the oral and dental phenotype are rare.

**Case presentation:** We describe the clinical presentation and periodontal findings in a 20-year-old Japanese man with previously diagnosed Prader-Willi syndrome. Clinical and radiographic findings confirmed the diagnosis of periodontitis. The most striking oral findings were anterior open bite, and crowding and attrition of the lower first molars. Periodontal treatment consisted of tooth-brushing instruction and scaling. Home care involved recommended use of adjunctive chlorhexidine gel for tooth brushing twice a week and chlorhexidine mouthwash twice daily. Gingival swelling improved, but further treatment will be required and our patient's oral hygiene remains poor. The present treatment of tooth-brushing instruction and scaling every three weeks therefore only represents a temporary solution.

**Conclusions:** Rather than being a direct result of genetic defects, periodontal diseases in Prader-Willi syndrome may largely result from a loss of cuspid guidance leading to traumatic occlusion, which in turn leads to the development of periodontal diseases and dental plaque because of poor oral hygiene. These could be avoided by early interventions to improve occlusion and regular follow-up to monitor oral hygiene. This report emphasizes the importance of long-term follow-up of oral health care by dental practitioners, especially pediatric dentists, to prevent periodontal disease and dental caries in patients with Prader-Willi syndrome, who appear to have problems maintaining their own oral health.

## Introduction

Prader-Willi syndrome (PWS) is a complex multi-system genetic disorder that results from abnormalities in the critical region of chromosome 15q11.2-q13, including paternal interstitial deletion, maternal uniparental disomy and imprinting defects [1,2]. PWS is characterized by infantile hypotonia, poor suck, hyperphagia and subsequent obesity, hypogonadism, mental retardation and various learning disabilities. In addition, PWS is associated with a variety of musculoskeletal abnormalities including scoliosis, short hands and feet, facial dysmorphism, narrow hands with straight ulnar border, delayed bone age and joint hyperlaxity. Characteristics of this

syndrome indicate hypothalamic dysfunction, and the incidence of the disorder is estimated at 1 in 10,000 to 25,000 individuals. The disorder can be divided into several stages [1,2]. The neonatal stage is mainly characterized by severe hypotonia and poor suck, which improves with age. Hyperphagia and subsequent obesity present in infancy, and small stature, developmental delay and behavioral problems (rigidity, stubbornness) are manifested during childhood. Adolescence is characterized by incomplete and delayed puberty, infertility, and deterioration of oppositional behavior (persistence of annoying behaviors, tantrums, and obsessive-compulsive behavior). Management of PWS, therefore, requires a multidisciplinary professional, parental and social approach to reduce morbidity and improve quality of life [3].

\* Correspondence: ipshinya@dent.osaka-u.ac.jp

Department of Periodontology, Division of Oral Biology and Disease Control, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan


Previously described oral and dental features of PWS include hypoplastic enamel [4,5], rampant caries [4,5], and dental erosion [6]. With respect to periodontal diseases, only one previous report has documented early-onset periodontitis in a 12-year-old girl with PWS [7]. We report a case of PWS in a 20-year-old man who presented to our facility with severe and localized periodontitis.

#### Case presentation


A 20-year-old Japanese man presented with his father to our periodontic clinic at Osaka University Dental Hospital, Japan, because of his poor oral condition. His chief complaint was severely painful gums, which led to crying. He was unable to provide detailed information about when and how this problem had started. His father told us that our patient had thought there was a gingival problem since childhood, had complained of gingival pain for the previous six months, and had been unable to brush his teeth for the last two weeks. Our patient's height was 153 cm and his weight was 62 kg. His medical history included a three-month hospital stay caused by low birth weight and cyanosis just after birth. A clinical diagnosis of PWS had been made on

the basis of symptoms such as hypotonia, genital hypoplasia, acromicria (short hands and feet) and genetic testing.

An intra-oral examination revealed poor oral hygiene with heavy generalized plaque throughout the permanent dentition. His gingival tissues showed marginal redness, swelling, and food impaction (Figure 1). An apparent anterior open bite, increasing overjet, an anterior crowded arch and malpositioning of the teeth were noted. In addition, circular caries and attrition of the mandibular first molars were present. Pocket depths ranged from 4 mm to 8 mm. Mobility grade 2 was present in the mandibular left second premolar. We tried to measure the pocket depth and clinical attachment level at his first visit. Unfortunately, however, our patient did not allow the pocket measurement because of pain. Thus, we could not perform the conventional pocket measurement and examined only the mesial and buccal/labial pockets. Periapical radiographs disclosed localized vertical bone resorption (mesiolateral of maxillary right first molar and mesiolateral of mandibular left first molar) (Figure 2). Of particular note, the mesiopalatal pocket depth of the maxillary right first molar was 8 mm.



**Figure 1** Intra-oral clinical appearance at initial visit.



**Figure 2** Baseline full-mouth periapical radiograph.


Based on pocket measurements and an X-ray examination, our patient was diagnosed with localized periodontitis. In addition, our patient exhibited several caries lesions from the mandibular right anterior teeth to the left molars. An orthopantomogram (Figure 3) showed full permanent teeth with unerupted lower third molars. There was no family history of periodontitis.

Advice on periodontal treatment was provided in the presence of one of our patient's parents. This included oral hygiene instructions on how to control plaque using a manual toothbrush (Sam Friend Supersoft #300; Sun Dental, Osaka, Japan), 0.2% w/w chlorhexidine mouth rinse (ConCool F; Weltech, Osaka, Japan) and 1% v/w chlorhexidine gel (ConCool Gelcoat F; Weltech). Professional scaling was also performed to remove supragingival plaque. Our patient kept his treatment


appointments with his father every three weeks, but his plaque control was poor. His father told us that our patient was motivated to brush his teeth and did so happily, but sometimes he fell asleep without brushing because of daytime somnolence; a common occurrence in PWS [3]. He refused to allow his parents to help him brush his teeth. Furthermore, malpositioning of the teeth and difficulties with hand and wrist movements inhibited adequate plaque control. After three visits to the clinic our patient had become accustomed to the dental treatment, and subgingival scaling was performed using an ultrasonic scaler. However, active treatments such as root planing and periodontal surgery were not employed because of poor plaque control. Both toothbrushing instruction (TBI) and subgingival scaling were performed every three weeks. Although some gingival inflammation remained, his gingival swelling and redness were reduced by six months after his first visit (Figure 4).

### Discussion

Most reports on the dental findings in PWS have focused on the presence of rampant caries, tooth wear, delayed tooth eruption, and hypoplastic enamel [4-6]. However, little is known about periodontal diseases in PWS. To the best of our knowledge, the only report in the English literature concerned a case of early-onset periodontitis in a 12-year-old girl with PWS [7]. The present report demonstrates the presence of moderate-to-severe periodontal destruction in a patient with PWS.



**Figure 3** Panoramic radiograph.



**Figure 4** Clinical image at six months showing some improvement of gingival swelling.

Several researchers have reported severe periodontal diseases in patients with systemic genetic disorders such as Marfan syndrome (MFS), Ehlers-Danlos syndrome (EDS) and Down's syndrome (DS), which are accompanied by connective tissue disorders characterized by joint hypermobility and scoliosis. MFS is caused by mutations in the fibrillin-1 gene on chromosome 15q21.1, leading to abnormalities in the connective tissue matrix [8]. Straub *et al.* reported that inflammatory periodontal breakdown in a patient with MFS was caused by abnormalities in the periodontal connective tissue rather than being attributable to the primary biochemical changes of MFS [9]. EDS comprises a heterogeneous group of inherited connective tissue disorders characterized by joint laxity, chronic joint pain, skin hyperextensibility, tissue fragility and scoliosis [10]. EDS can be divided into 11 phenotypes, and periodontal diseases have been reported in EDS types I and VIII. The pathogenesis of these subtypes of EDS are unknown. The periodontal disease in EDS type I is localized,

whereas EDS type VIII is characterized by ligneous periodontitis or persistent hyperplastic gingivitis [11]. DS is a chromosomal disorder that results from an extra copy of chromosome 21 (trisomy 21). Patients with DS have a variety of associated medical conditions, including joint hypermobility and ligamentous laxity [12]. The immune alterations in DS, including impaired neutrophil chemotactic function, are responsible for the defensive mechanisms in periodontal disease, which are frequently experienced by subjects with DS [13,14]. As in MFS, EDS and DS, musculoskeletal abnormalities such as scoliosis, joint hyperlaxity, delayed bone age and osteoporosis, are also clinical features of PWS [3]. Although a number of imprinted genes have been mapped to the PWS region at 15q11.2-q13, there is no case normal paternal copy of 15q11-q13 with inheritance consistent with a single mutated gene, suggesting that PWS is a multigenic syndrome [15]. Furthermore, there is no gene related to the connective tissue matrix in the PWS region. The periodontal breakdown

demonstrated in this case report may have been the combined result of poor plaque control, crowding, tooth malposition, and occlusal trauma. In particular, the presence of plaque and inflammation in our patient would appear to be a primary etiology, with occlusal imbalances as a contributing factor. Additionally, the interactions of multiple genes affected in PWS may increase the susceptibility to periodontal breakdown via effects on the host immune response; a recent report has shown that an overactivation of the innate immune system and increased chronic low-grade inflammation has been observed in patients with PWS [16]. Periodontal disease in PWS, as shown in this report, is considered to be similar to cases of patients with DS with regard to traumatic occlusion, mouth breathing with an open bite, poor plaque control and immune alternations. Further studies are needed to clarify the relationship between the genetic defect(s) and periodontal disease in PWS.

A recent study that surveyed the orodental characteristics of 15 patients with PWS with early multidisciplinary follow-up at the university hospital reported low incidence of caries and enamel hypoplasia [6]. However, our patient did not receive a multidisciplinary medical follow-up, and it is possible that such follow-up, including dental procedures, could have prevented the development of periodontal disease and caries. Learning disabilities in individuals with PWS mean that prolonged treatments such as periodontal surgery with local anesthesia or oral self-care with several cleaning aids such as tooth brushing, inter-dental brushing and dental flossing, which require tolerance and technique on the part of the patient, are hardly applicable. Thus, oral preventive treatments or interventions from early childhood, such as optimal plaque control and occlusal improvement by orthodontic treatments, should be implemented and may be beneficial for patients with PWS.

## Conclusions

To the best of our knowledge, we describe the first case reported in the literature of periodontal diseases in a patient with PWS with severe malposition of his teeth and traumatic occlusion. Because of the difficulty in oral self-care for patients with PWS, we believe that both medical and dental doctors should be involved in maintaining oral health care of such patients, with early intervention and long-term follow-up.

## Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

## Authors' contributions

MY and SM drafted the manuscript. MY, HH, MK, TN, SY and MK were involved in our patient's care and follow-up. All authors have read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

Received: 20 December 2010 Accepted: 28 July 2011

Published: 28 July 2011

## References

1. Donaldson MD, Chu CE, Cooke A, Wilson A, Greene SA, Stephenson JB: The Prader-Willi syndrome. *Arch Dis Child* 1994, **70**:58-63.
2. Bittel DC, Butler MG: Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. *Exp Rev Mol Med* 2005, **7**:1-20.
3. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M: Recommendations for the diagnosis and management of Prader-Willi syndrome. *J Clin Endocrinol Metab* 2008, **93**:4183-4197.
4. Bazopoulou-Kyrkanidou E, Papagianoulis L: Prader-Willi syndrome: report of a case with special emphasis on oral problems. *J Clin Pediatr Dent* 1992, **17**:37-40.
5. Anavi Y, Mintz SM: Prader-Labhart-Willi syndrome. *Ann Dent* 1990, **49**:26-29.
6. Bailleul-Forestier I, Verhaeghe V, Fryns JP, Vinckier F, Declerck D, Vogels A: The oro-dental phenotype in Prader-Willi syndrome: a survey of 15 patients. *Int J Paediatr Dent* 2008, **18**:40-47.
7. Greenwood RE, Small IC: Case report of the Prader-Willi syndrome. *J Clin Periodontol* 1990, **17**:61-63.
8. McKusick VA: The defect in Marfan syndrome. *Nature* 1991, **352**:279-281.
9. Straub AM, Grahame R, Scully C, Tonetti MS: Severe periodontitis in Marfan's syndrome: a case report. *J Periodontol* 2002, **73**:823-826.
10. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ: Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). *Am J Med Genet* 1998, **77**:31-37.
11. Perez LA, Al-Shammari KF, Giannobile WV, Wang HL: Treatment of periodontal disease in a patient with Ehlers-Danlos syndrome. A case report and literature review. *J Periodontol* 2002, **73**:564-570.
12. Caird MS, Wills BP, Dormans JP: Down syndrome in children: the role of the orthopaedic surgeon. *J Am Acad Orthop Surg* 2006, **14**:610-619.
13. Reuland-Bosma W, van Dijk LJ: Periodontal disease in Down's syndrome: A review. *J Clin Periodontol* 1986, **13**:64-73.
14. Izumi Y, Sugiyama S, Shinozuka O, Yamazaki T, Ohyama T, Ishikawa I: Defective neutrophil chemotaxis in Down's Syndrome patients and its relationship to periodontal destruction. *J Periodontol* 1989, **60**:238-241.
15. Nicholis RD: Incriminating gene suspects, Prader-Willi style. *Nat Genet* 1999, **23**:132-134.
16. Viardot A, Sze L, Purtell L, Sainsbury A, Loughnan G, Smith E, Herzog H, Steinbeck K, Campbell LV: Prader-Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. *J Clin Endocrinol Metab* 2010, **95**:3392-3399.

doi:10.1186/1752-1947-5-329

Cite this article as: Yanagita et al.: Periodontal disease in a patient with Prader-Willi syndrome: a case report. *Journal of Medical Case Reports* 2011 **5**:329.

## 特集I

## 樹状細胞機能の可塑性

ニコチンによる  
樹状細胞の機能修飾\*柳田 学\*\*  
森 健太\*\*  
村上 伸也\*\*

Key Words : nicotine, dendritic cells, immunomodulation

## はじめに

喫煙により肺癌や口腔咽頭癌, 循環器系疾患, 慢性閉塞性肺疾患, 歯周病の発症・重篤化のリスクは有意に増加する<sup>1)2)</sup>。また, 受動喫煙は, 非喫煙者の健康状態に影響を及ぼす可能性も指摘されている。タバコ煙は粒子相成分とガス相成分によって構成されており, その中には物質名が確認されているもので約4,500種類以上の化学物質が含まれているとされている<sup>3)</sup>。その中でもタバコ煙主成分であるニコチンは粒子相成分, ガス相成分のいずれにおいても多量に含まれており, 喫煙者の唾液中には非常に高濃度のニコチンが溶け込んでいることが知られている<sup>4)</sup>。口腔・鼻腔粘膜, 肺より取り込まれたニコチンをはじめとするタバコ煙に含まれる有害物質は, 粘膜局所の免疫担当細胞に直接的に曝露し, あるいは血流により遠隔組織・臓器の免疫担当細胞に作用して, その免疫機能を制御していることが明らかになりつつある。

免疫担当細胞の中で, 樹状細胞(dendritic cells; DC)は生体に広く分布する最も強力な抗原提示細胞である<sup>5)</sup>。その細胞機能はT細胞に抗原提示するだけでなく, さまざまな外来異物抗原や病原体を認識してサイトカイン産生や, 表面抗

原分子の発現を誘導する。また, DC自身が産生するサイトカイン・表面分子抗原の変化の結果, DCの分化・成熟に変化を及ぼすことが知られている。本稿ではニコチンと, 無数の成分で構成されているタバコ煙抽出物(cigarette smoke extracts; CSE)に対するDCの細胞機能制御について, 私たちの知見もまじえて述べる。

## ニコチン様アセチルコリン受容体

ニコチンは神経伝達物質であり, イオンチャネル型のレセプターであるニコチン様アセチルコリンレセプター(nicotinic acetylcholine receptor; nAChR)に結合する。nAChRは $\alpha 1 \sim 10, \beta 1 \sim 4, \gamma, \delta, \epsilon$ など多数のサブユニットが単独, もしくは複数のサブユニットの組み合わせによって5量体を構成し, 主に神経筋接合部におけるシグナル伝達に関与している<sup>6)</sup>(図1)。近年, nAChRを介した刺激が, 免疫担当細胞に対してさまざまな影響を与える可能性が示唆されている。たとえば,  $\alpha 7$ サブユニットを介したシグナルによりLPS刺激マクロファージからの炎症性サイトカイン産生が抑制されることが2003年に報告された<sup>7)</sup>。次いで,  $\alpha 7$ サブユニットを介した抗炎症性経路はJak2-STAT3を活性化して, 最終的にNF- $\kappa$ Bの転写活性を抑制することが示された<sup>8)</sup>。興味深いことに私たちは, ヒト単球・単球由来DCにおいて $\alpha 1 \sim 7, \beta 2$ および $\beta 4$ サブユニットのmRNAが発現している

\* Nicotine-induced immunomodulation of dendritic cells.

\*\* Manabu YANAGITA, D.D.S., Ph.D., Kenta MORI, D.D.S. &amp; Shinya MURAKAMI, D.D.S., Ph.D.: 大阪大学大学院歯学研究科口腔分子免疫制御学講座(口腔治療学教室)[☎565-0871 大阪府吹田市山田丘1-8]; Department of Periodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, JAPAN




図1 ニコチン様アセチルコリン受容体の構造(文献<sup>6)</sup>より引用改変)

のを確認するとともに、ニコチンにより単球・単球由来DC内のカルシウムイオン濃度が一過性に上昇することを認めた(未公表データ)。すなわち、ヒト単球において機能的なnAChRが発現していると考えられる。

### ニコチンによるDCの免疫機能調節

喫煙習慣とさまざまな全身疾患の罹患率増加には相関性があり、その一因として慢性的なタバコ煙吸引による免疫機能の変化が関与しているとはじめて認識されたのは1960年代である<sup>9)</sup>。その後、慢性閉塞性肺疾患の病態解明のため肺胞マクロファージや好中球に対するニコチン・CSEの影響について研究が進められてきた。また、Gengらは長期間のニコチン処理によりT細胞アナジーが誘導されることを報告した<sup>10)</sup>。しかしながら、DCの免疫機能に及ぼすニコチン・CSEに関する研究は、2003年のNouri-ShiraziらとAicherらの報告がはじめてであり<sup>11)12)</sup>、両報告ともヒト単球から分化させたDCにニコチン刺激を加えた後の免疫応答を検討している。

Nouri-Shiraziらは、ニコチンをDC分化後あるいは分化時に添加した後に、DCをLPS刺激した際のIL-12の産生、T細胞増殖活性、T細胞からのIFN- $\gamma$ 産生を検討し、コントロール群と比較してこれらの機能が抑制されることを報告した<sup>11)13)</sup>。しかしながら、Aicherらの報告ではニコチン刺激のみでDCからのIL-12産生、CD54、CD86、HLA-DRといった表面抗原の発現、T細胞増殖活性をそれぞれ増強するというものであり<sup>12)</sup>、この2グループの示した結果は相反するものであった。一方Vassalloらは、ニコチンはDCのphenotypeに

変化を及ぼさないものの、CSE存在下ではLPS刺激で誘導されるIL-12産生量の減少とIL-10産生量の増強、CD40、CD80、CD86発現およびT細胞増殖活性の減弱とT細胞からのIL-4産生増強について報告した<sup>14)</sup>。同グループはやはりCSE存在下でDCはERK依存的にIL-12/IL-23の発現を減少させることを報告している<sup>15)16)</sup>。

マウスを用いた系では骨髄由来DCにニコチンを添加してもphenotypeに変化はないものの、DCへの分化過程でニコチンが存在するとIL-10、IL-12産生の減弱、T細胞からのIFN- $\gamma$ 産生を抑制するという報告<sup>17)</sup>や、骨髄由来DC分化後にCSEで刺激するとケモカインCCL3、CXCL2産生誘導、CD4陽性T細胞の増殖活性は減弱させる一方、CD8陽性T細胞の増殖活性を増強するという報告もある<sup>18)</sup>。また、骨髄由来DCにニコチン刺激した際、CD80、CD86、MHC class I、class IIの発現上昇とT細胞増殖活性の増強、抗癌作用を有するとの報告もある<sup>19)</sup>。これらの報告を簡略したものを表1に示す。

これまでの報告をまとめると、ニコチンにより免疫応答がTh1型あるいはTh2型のどちらにも制御されること、あるいはニコチン自体ではDCの機能に変化を及ぼさないもののCSE存在下ではDCの免疫応答はTh2型となることなど、はっきりとした統一見解はでていない。しかしながら、ニコチンを含めたタバコ煙そのものがDCの機能修飾になんからの影響を及ぼしていることは明らかである。

私たちは、喫煙歴のある歯周病患者の病態が、非喫煙患者よりも重篤であることの一因は、喫煙による免疫系の攪乱であると仮説をたて、抗